Daniel Rauch
Spital STS(CH)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Lymphoma Diagnosis and Treatment, Head and Neck Cancer Studies
Most-Cited Works
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,656 cited
- → Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial(2015)385 cited
- → Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial(2017)182 cited
- → Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)(2016)137 cited
- → Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK(2008)127 cited
- → Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial(2017)120 cited
- → Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers(2019)115 cited
- → Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)(2011)105 cited
- → A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity(2005)102 cited
- → Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07(2012)85 cited